Best Useful Articles

St. Jude Medical Announces European Approval Of Smaller, Higher Power ICD And CRT-D Devices With New Heart Failure Monitors

St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval and first implants of its Fortify(TM) and Fortify ST implantable cardioverter defibrillators (ICD) and Unify(TM) cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry. The Fortify ICD and Unify CRT-D feature advanced battery technology and circuitry that allow for a smaller device, with more energy capacity and rapid charge times, all while increasing device longevity.

Bioheart Launches First US FDA Approved Clinical Trial That Tests Gene-Modified Stem Cell Therapy In Patients With Congestive Heart Failure

Bioheart, Inc., (OTCBB:BHRT) announced that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells, that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials. The REGEN trial is designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein. The SDF-1 protein is a molecule in the human body that, after an injury, is naturally released by most tissues to attract stem cells.

MAQUET Cardiovascular Announces Long-Term Follow-Up Data From Landmark 'SMART' Study Reinforce Positive Results For Patients Undergoing OPCAB

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced that long-term results from the landmark SMART (Surgical Management of Arterial Revascularization) study will be presented tomorrow to attendees of the Society of Thoracic Surgeons's 46th Annual Meeting by John Puskas, M.D., Chief of Cardiac Surgery, Emory Crawford Long Hospital, Associate Chief of Cardiothoracic Surgery, Emory University, and SMART Study lead investigator. The data provide confirmation of the efficacy of performing Coronary Artery Bypass Graft surgery (CABG) while the patient's heart continues to beat a procedure known as Off-Pump Coronary Artery Bypass (OPCAB).

Medtronic Receives FDA Approval For First Replacement Heart Valve Implanted Without Surgery

In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody® Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first transcatheter heart valve to receive FDA approval. Delivered through a catheter requiring only a small incision, the Melody valve will benefit children and adults who are born with a malformation of their pulmonary valve, which is the valve between the heart and lungs. These patients often require open-heart surgery to restore effective blood flow to their lungs.

Bypass Procedure Used During Infant Heart Surgery Does Not Impair Later Neurological Outcomes

Congenital heart defects (CHD) are the most common birth defects in humans, affecting 8 per 1000 live births with one-third of affected children requiring intervention in early infancy. Increasing numbers of survivors combined with developmental expectations for independence, behavioral self-regulation and academic achievement have led to a growing identification of neurobehavioral symptoms in some survivors. A study now suggests that a cooling technique often used in heart operations does not impair neurological outcomes. Congenital heart disease and its treatment were originally thought to potentially increase neurologic injury in these patients. The technique of deep hypothermic circulatory arrest (DHCA) is used in order to repair these congenital cardiac defects by providing a bloodless surgical field, which may facilitate completion of the best physiologic repair, and decrease the duration of blood exposure to the bypass circuit.

Cardium Provides Update On Commercial Development Plans For Generx Angiogenic Therapy For Heart Disease At 2010 Cell Gene Therapy Forum

Cardium Therapeutics (NYSE Amex: CXM) reported that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease. The update was presented by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer at the annual 2010 Cell & Gene Therapy Forum in Washington, D.C. on January 25, 2010. Cardium Biologics reported on the following findings and plans: (1) As previously announced, based on an agreement with the FDA, Generx would be re-formulated to increase its shelf life, and further formulation enhancements are expected to allow for storage using a standard freezer (rather than at -70 degrees C), and potentially a lyophilized version for refrigerated storage.

Atrial Fibrillation Treatment Using Specialized Catheter Results In Better Outcomes Compared To Drug Therapy

Use of catheter ablation, in which radiofrequency energy is emitted from a catheter to eliminate the source of an irregular heartbeat, resulted in significantly better outcomes in patients with paroxysmal atrial fibrillation (intermittent cardiac rhythm disturbance) who had not responded previously to antiarrhythmic drug therapy, according to a study in the January 27 issue of JAMA. Atrial fibrillation (AF) represents an important public health problem, with patients having an increased long-term risk of stroke, heart failure and all-cause death. Although antiarrhythmic drugs are generally used as first-line therapy to treat patients with AF, they are associated with cumulative adverse effects over time and their effectiveness remains inconsistent, according to background information in the article.

Cord Blood-Derived CD133 Cells Improve Cardiac Function After Myocardial Infarction

Researchers at the PontifĂ cia Universidade Catolica do Parana and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be an alternative to rescue impaired stem cell function in the sick and elderly. The results, which appear in the January 2010 issue of Experimental Biology and Medicine, show that expanded cells ex vivo exhibited increased expression of mature endothelial cells markers and formed tubule-like structures in vitro.

Engineers Seek To Stem Massive, Deadly Flow Of Heart Disease

Virginia Tech researcher Pavlos Vlachos and his students in the College of Engineering have a tall order to tackle: Stem the grim progression of heart disease, which kills hundreds of thousands of people each year in the United States alone. Vlachos, an associate professor of mechanical engineering and director of the Advanced Experimental Thermofluid Engineering Research Laboratory, is waging this fight with what he calls his four children. That's not a condescending term for his researchers, but a parental pride in the series of cardiac-related projects he's working on. Vlachos literally treats these research projects as a parent would treat his or her children.

FDA Approves First Percutaneous Heart Valve

The U.S. Food and Drug Administration approved the Medtronic Melody Transcatheter Pulmonary Valve and Ensemble Delivery System, the first heart valve to be implanted through a catheter, or tube, in a leg vein and guided up to the heart. This new approach to the treatment of adults and children with previously implanted, poorly functioning pulmonary valve conduits can delay the need for open-heart surgery. Conduits are surgically implanted valves used to treat congenital heart defects of the pulmonary valve. Patients with congenital heart defects have narrowed, leaky, or missing pulmonary valves that impede the proper flow of blood from the heart's right ventricle to the pulmonary artery, which then sends the blood on to the lungs for oxygenation.

Best Useful Articles © Dimitrov Dmitriy
Designer Dimitrov Dmytriy